If orforglipron can be manufactured at scale for a fraction of the cost of injectable alternatives, and if its oral format eliminates the injection barriers that prevent millions from starting therapy, the public health impact could be measured in reduced cardiovascular events, fewer diabetes-related amputations, decreased obesity-related cancer incidence, and extended healthy lifespan across populations
The objective is to design benefit strategies that improve health outcomes, manage pharmacy spend, and support long-term workforce wellbeing
The 2023 WHO world malaria report
Food and Drug Administration (FDA) for weight loss, there is no recommended dose for this purpose
[1] GLP-1 agonists: the next big disruptor in society [2] Obesity Profile: short statistical commentary May 2024 GOV.UK
How Skinny Fat Happens on Tirzepatide GLP-1s like tirzepatide and semaglutide encourage weight loss by regulating how much you feel like eating, and how full you stay after a meal